Alliancebernstein L.P. Aligos Therapeutics, Inc. Transaction History

Alliancebernstein L.P.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2021 May 06, 2021	SELL	$19.1 - $34.94 $955,000 - $1.75 Million	-50,000 Closed	0 $0
Q4 2020 Feb 08, 2021	BUY	$13.2 - $32.74 $660,000 - $1.64 Million	50,000 New	50,000 $1.38 Million

227K

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $431M
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

Stay updated on Alliancebernstein L.P. with notifications on news.